Voices
Drug discovery evolves: Jump-starting the transition from animal models to human preclinical models
The limitations of animal and in vitro studies are beginning to change with the advent of organ-on-a-chip technologies. Check out this article about AIM Biotech on drugdiscoverytrends.com.
The AIM Biotech product family is getting multiplied
AIM’s 3D cell culture technology has always been about empowering preclinical research with better data and more predictive, humanized models. Powered by technology developed in the research labs of Dr. Roger Kamm at the Massachusetts Institute of Technology, the...
Building a functional human vascular disease model using AIM Biotech 3D cell culture technology
Understanding the interactions between endothelial cells and vascular smooth muscle cells is critical for the study of vascular disease. Yet, there are few existing models which can simply and reliably recapitulate the cellular crosstalk in human microvascular...
Immunotherapy month: T-cells and transplants—avoiding cancer relapse after liver transplantation using AIM Biotech’s organ-on-a-chip assays
To round out our month-long series highlighting research on adoptive T cell immunotherapy, today we’ll take a look at how scientists are modifying T cells to help prevent cancer relapse on liver transplanted patients, harnessing AIM Biotech’s technology. In cases...
Immunotherapy month: Receptor conflict—keeping cancer-killing T cells on-target using AIM Biotech’s organ-on-a-chip assays
This month on AIM’s Voices feed is dedicated to the fascinating research being done on adoptive T cell immunotherapy. Today, we’ll take a look at how scientists used AIM Biotech’s organ-on-a-chip technology to build on previous studies and refine this promising new...
Immunotherapy month: The immune system workaround—suppressing immune checkpoint expression to attack tumors with T cells in AIM Biotech’s organ-on-a-chip
You learned last week how AIM Biotech’s organ-on-a-chip is the perfect model for studying T cell migration to a 3D tumor while examining adoptive T cell immunotherapy. Today, we’ll discuss how scientists used the same technology to discover a major improvement to...
Immunotherapy month: Tracking T cell migration for use in immunotherapy using a 3D organs-on-a-chip
This month we are exploring the details of adoptive T cell Immunotherapy and how AIM Biotech’s technology facilitated the development of this relevant technique for cancer treatment. In adoptive T cell immunotherapy, the body’s immune T cells are engineered to...
Developing a new adoptive T cell immunotherapy with AIM’s organ-on-a-chip
This month's theme: exploring studies to develop T cell immunotherapy, powered by AIM Biotech AIM Biotech’s organ-on-a-chip is a useful tool for preclinical studies. During this month, we’ll showcase how research powered by AIM Biotech’s organ-on-a-chip contributed...
Featured study: Mimicking a tumor in a chip to study new lung cancer therapies
Small cell lung carcinoma:Tackling a resistant cancer AIM Biotech’s organ-on-a-chip has again demonstrated again how its technology allows the simulation of a tumor to study the migration of T cells in a human tumor environment. Mahadevan and coll. studied a...
Featured study: modeling the human tumor microenvironment for IL-15 on AIM technology
Our applications development manager Lim Sei Hien discusses one recent study in cancer immunotherapy that benefited from the humanized technology in AIM Biotech’s organ-on-a-chip.
The secret to better blood-brain barrier models
The blood-brain barrier is notoriously difficult to model in the lab—until now. AIM's proven technology and world-class contract research lab can get you better BBB data faster with our human-on-a-chip in vitro models.
From the expert: Roger Kamm’s insights on M-CELS
AIM Biotech co-founder Roger Kamm, PhD gives a sneak peek into his opening keynote at next week's free workshop about M-CELS. Read on to see his personal insights as a leader in this growing field.
